Canaccord Genuity Group restated their hold rating on shares of Smith & Nephew (NYSE:SNN – Free Report) in a research note published on Monday,Benzinga reports. Canaccord Genuity Group currently has a $27.00 price objective on the medical equipment provider’s stock.
SNN has been the topic of several other reports. StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 26th. UBS Group cut Smith & Nephew from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 12th. Four research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $27.00.
View Our Latest Stock Report on Smith & Nephew
Smith & Nephew Price Performance
Smith & Nephew Increases Dividend
The business also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be paid a $0.447 dividend. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, March 28th. Smith & Nephew’s dividend payout ratio is currently 41.20%.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of SNN. Principal Securities Inc. boosted its stake in shares of Smith & Nephew by 87.6% in the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 691 shares in the last quarter. R Squared Ltd acquired a new position in Smith & Nephew in the fourth quarter valued at about $41,000. National Bank of Canada FI grew its stake in Smith & Nephew by 36.5% during the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 446 shares during the last quarter. Hara Capital LLC increased its holdings in shares of Smith & Nephew by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 1,957 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Smith & Nephew by 31.8% in the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock valued at $73,000 after acquiring an additional 718 shares during the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.
Smith & Nephew Company Profile
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Read More
- Five stocks we like better than Smith & Nephew
- How to Buy Cheap Stocks Step by Step
- Can TikTok Stock Picks Really Make You Rich?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- The “Quality” Rotation: Back to Basics Investing
- What Are Dividend Challengers?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.